日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Ixabepilone-induced mitochondria and sensory axon loss in breast cancer patients

伊沙匹隆诱导乳腺癌患者线粒体和感觉轴突丢失

Ebenezer, Gigi J; Carlson, Karen; Donovan, Diana; Cobham, Marta; Chuang, Ellen; Moore, Anne; Cigler, Tessa; Ward, Maureen; Lane, Maureen E; Ramnarain, Anita; Vahdat, Linda T; Polydefkis, Michael

Phase II trial of bortezomib alone or in combination with irinotecan in patients with adenocarcinoma of the gastroesophageal junction or stomach

一项针对胃食管交界处或胃腺癌患者的II期临床试验,评估硼替佐米单药或联合伊立替康的疗效。

Ocean, Allyson J; Christos, Paul; Sparano, Joseph A; Shah, Manish A; Yantiss, Rhonda K; Cheng, Jonathan; Lin, Juan; Papetti, Michael; Matulich, Dan; Schnoll-Sussman, Felice; Besanceney-Webler, Christen; Xiang, Jenny; Ward, Maureen; Dilts, Kaili Temple; Keresztes, Roger; Holloway, Shannon; Chen, Eric X; Wright, John J; Lane, Maureen E

Overcoming the response plateau in multiple myeloma: a novel bortezomib-based strategy for secondary induction and high-yield CD34+ stem cell mobilization.

克服多发性骨髓瘤的反应平台期:一种基于硼替佐米的新型策略,用于二次诱导和高产 CD34+ 干细胞动员

Niesvizky Ruben, Mark Tomer M, Ward Maureen, Jayabalan David S, Pearse Roger N, Manco Megan, Stern Jessica, Christos Paul J, Mathews Lena, Shore Tsiporah B, Zafar Faiza, Pekle Karen, Xiang Zhaoying, Ely Scott, Skerret Donna, Chen-Kiang Selina, Coleman Morton, Lane Maureen E

Incremental increase in VEGFR1⁺ hematopoietic progenitor cells and VEGFR2⁺ endothelial progenitor cells predicts relapse and lack of tumor response in breast cancer patients.

VEGFR1âº造血祖细胞和VEGFR2âº内皮祖细胞的逐渐增加可预测乳腺癌患者的复发和肿瘤反应不足

Jain Sarika, Ward Maureen M, O'Loughlin Jennifer, Boeck Marissa, Wiener Naomi, Chuang Ellen, Cigler Tessa, Moore Anne, Donovan Diana, Lam Christina, Cobham Marta V, Schneider Sarah, Christos Paul, Baergen Rebecca N, Swistel Alexander, Lane Maureen E, Mittal Vivek, Rafii Shahin, Vahdat Linda T